DID YOU KNOW? DTIC has over 3.5 million final reports on DoD funded research, development, test, and evaluation activities available to our registered users. Click HERE
to register or log in.
Monosodium Luminol for Improving Brain Function in Gulf War Illness
Technical Report,30 Sep 2014,29 Sep 2015
Texas A and M University System College Station United States
Pagination or Media Count:
The goal of this project is to ascertain whether administration of monosodium luminol-GVT MSL-GVT, an antioxidant drug from Bach Pharma in a rat model of Gulf war illness GWI would alleviate mood and memory dysfunction and anxiety associated with Gulf war illness GWI. Specific Aim 1 studies are focused on quantifying the efficacy of different doses of MSL-GVT for suppressing oxidative stress and inflammation and improving neurogenesis in the hippocampus of rats exposed to GWI-related GWIR chemicals and stress GWI-rats. Specific Aim 2 studies are focused on examining whether long-term administration of an apt dose of MSL-GVT would alleviate mood and memory dysfunction and anxiety in GWI-rats, using a battery of behavioral tests. During the past year, a portion of experiments for Specific Aim 1 was performed 1 Exposure of rats to GWIR-chemicals and moderate stress. 2 Oral administration of different doses of MSL-GVT, 4-months after the exposure. 3 Mood and memory function analyses using a few behavioral tests. 4 Analyses of oxidative stress using biochemical and molecular biological assays. The data collected so far suggest that administration of higher doses of MSLGVT to GWI-rats improves mood and memory function with decreased concentration of malondialdehyde a by product of oxidative stress and normalized expression of oxidative stress responsive genes.
APPROVED FOR PUBLIC RELEASE